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Abstract: 
 
HIV infection is more common among smokers than nonsmokers, and, remarkably, HIV-infected 
individuals are about 3 times more likely to smoke than the uninfected general population. 
However, the relationship between tobacco smoking and HIV/AIDS disease progression remains 
controversial. 
 
In this study, we demonstrate a potent enhancing effect of aqueous tobacco smoke extract (TSE) 
on HIV infectivity that is nicotine-independent. This increased infectivity is neither NF-κB 
mediated nor a direct result of oxidative stress, as it cannot be blocked by antioxidants. On the 
contrary, TSE itself was found to possess significant antioxidant potential, enabling it to protect 
the viability of both infected cells and HIV virions in the presence of peroxide. Assessment of 
TSE-induced alterations in cellular gene expression that may be involved in increasing HIV 
infectivity in T cells showed that TSE up-regulates some genes known to be capable of 
enhancing HIV and HCV infection, or protecting HIV, but down-regulates several genes 
involved in cellular defense and antigen presentation. 
 
These results demonstrate that tobacco smoke can enhance HIV infectivity, possibly by a 
combination of direct (antioxidant) and indirect (gene-based) mechanisms. This raises the 
concern that smoking may thereby increase the risk of acquisition or progression of HIV 
infection. 
 
Keywords: Tobacco | Smoke | HIV-1 | Infectivity 
 
Article: 
 
Abbreviations: FRAP, ferric reducing ability of plasma; t-BOOH, tert-butyl-hydroperoxide; 
Trx, thioredoxin; TSE, tobacco smoke extract 
 
1. Introduction 
 
The relationship between tobacco smoking and HIV/AIDS progression still remains 
controversial (Furber et al., 2007). Some studies suggest that tobacco smoking by HIV-1-
seropositive individuals is associated with a more rapid progression to AIDS (Crothers et al., 
2005, Nieman et al., 1993). In contrast, a survey that enrolled 2499 HIV-1-seropositive men for 
up to 9 years found that tobacco smoking does not have a major effect on the progression of 
HIV-1 infection to AIDS (Galai et al., 1997). However, one of the stronger conclusions 
presented recently is that smoking increases the risk of becoming infected with HIV (Furber et 
al., 2007). Evidence also suggests that AIDS patients who smoke have a higher incidence of 
dementia (Burns et al., 1996). 
 
Perhaps partly because of these controversies and inconsistencies in study results, and because 
the life expectancies of AIDS patients have been increased dramatically since highly active 
antiretroviral therapy (HAART) became the standard of care, comparatively little attention has 
been paid to the interactions between tobacco smoking and HIV/AIDS. A decreased awareness 
among health care providers of current smoking behaviors of HIV-positive compared to HIV-
negative veterans has been reported (Crothers et al., 2007). However, it would be unwise to 
ignore studies suggesting that HIV/AIDS patients who are smokers suffer more clinical 
complications such as pneumonia, oral candidiasis, hairy leukoplakia, vascular diseases, AIDS-
related malignancies and neuropathy (Conley et al., 1996, Elzi et al., 2006). At the same time, 
some of the benefits provided by HAART are negated in tobacco smokers (Feldman et al., 2006). 
Patients with HIV infection who smoke also have poorer health-related quality of life than 
nonsmokers (Turner et al., 2001). During pregnancy, tobacco smoking can increase risk of 
maternal-child HIV transmission and complications (Kalish et al., 1998, Turner et al., 1997). 
 
In defining the relation between tobacco smoking and HIV/AIDS, most research has been done 
based on epidemiological profiles; few studies have explored the possibility of direct interactions 
between tobacco constituents and/or smoking and actual viral replication in HIV/AIDS. 
 
Nicotine is the single tobacco constituent demonstrated to have at least the potential to stimulate 
the production of HIV-1, as has been shown using in vitro-infected alveolar macrophages 
(Abbud et al., 1995). Pretreatment of microglia with nicotine (300 μM) was shown to increase 
HIV-1 expression (Abbud et al., 1995). However, the median concentration of nicotine in the 
plasma of smokers does not usually exceed about 0.23 μM (Taylor et al., 1986), and at this 
concentration, nicotine showed no effect on HIV infection (Rock et al., 2008). 
 
Tobacco smoking is widely viewed as a source of oxidative stress. Significantly, oxidative stress 
can induce HIV replication, resulting in disease progression (Boelaert et al., 1996, Miller et al., 
1997). Smoking can induce the NF-κB activation pathway in lymphocytes via intracellular 
formation of peroxynitrite, through a reaction between smoke-derived NO and endogenously 
produced superoxide (Hasnis et al., 2007). However, when samples of alveolar air from smokers 
and non-smokers were analyzed for ethane using mass spectrometry, they showed no evidence 
that cigarette smoking is related to increased n-3 lipid peroxidation (Puri et al., 2008). Similarly, 
blood samples from clinically stable smoking and nonsmoking men with HIV/AIDS showed no 
striking differences in oxidative stress or antioxidant capacity (Cole et al., 2005). 
 
Here, an aqueous tobacco smoke extract (TSE) was used to study the direct effect of smoking on 
HIV infection and its effects on gene expression in human T cells. The data demonstrate that 
TSE can enhance HIV infectivity in a nicotine-independent manner, and, surprisingly, that TSE 
has significant antioxidant potential, capable of protecting cells and virions from oxidative 
damage. An mRNA microarray analysis of TSE-treated human T-cells suggests that a number of 
genes that are up-regulated can be related to HIV infection, whereas several genes involved in 
cell defense or redox functions are down-regulated by TSE treatment. 
 
2. Material and methods 
 
2.1. Preparation of aqueous tobacco smoke extract (TSE) 
 
Into 40 mL of sterile saline (PBS) in a water pipe-like apparatus (sidearm conical flask), 5 
cigarettes (Marlboro Light brand, Philip Morris, USA) were puffed through the PBS solution. 
The nicotine concentration in this TSE is typically around 100 μM, as measured with a standard 
method based on bromination of nicotine (Rai et al., 1994). This TSE is used throughout all these 
studies. Note that when diluted 100-fold in culture media (e.g., 2 μL TSE in 200 μL final volume 
of media), this would give a nicotine concentration of about 1 μM. 
 
2.2. Cell lines 
 
The TZM-bl cell line was obtained from the NIH AIDS Research and Reference Program (Cat # 
8129). This cell line was originally generated from JC53 cells (which express CD4 and the 
CCR5 HIV co-receptor) by introducing separate integrated copies of the luciferase and β-
galactosidase genes under control of the HIV-1 long terminal repeat (LTR) promoter/enhancer. 
This cell line is highly sensitive to infection with diverse isolates of HIV-1, and produces 
luciferase in proportion to the amount of replicating HIV; hence, it is useful for assessments of 
viral infectivity and relative viral titers or “pseudo viral load”. Hela, 293T and Jurkat cell lines 
were purchased from ATCC. TZM-bl cells, 293T cells, Hela cells or Jurkat cells were cultured at 
37 °C in 5% CO2, in RPMI 1640 or DMEM medium supplemented with glutamine (2 mM) and 
10% fetal bovine serum. 
 
2.3. Cell proliferation assay 
 
TZM-bl cells (1.2 × 104 per well) were plated in a 96-well plate and incubated with serial doses 
of TSE. At 48 h post-incubation, cell proliferation was measured by the MTT method. 
 
2.4. Preparation of HIV stocks 
 
pNL4-3 plasmid DNA was transfected into 293T cells with calcium phosphate transfection 
protocol (Fortin et al., 1997). 
 
2.5. TSE oxidation/reduction potential assays 
 
The ferric reducing power-based antioxidant capacity assay (Berker et al., 2007) and the FRAP 
method (Benzie and Strain, 1996) were both used as cell-free assays to measure TSE total 
antioxidant activity. Identical volumes of TSE, l-ascorbic acid or Fe+2 stock solutions were added 
to assay solution, and the absorbance at 700 nm or 595 nm, respectively, was measured. The 
human erythrocyte hemolysis assay was performed according to the procedure by Ajila and 
Prasada Rao (2008). Briefly, to 200 μL of 5% (v/v) suspension of erythrocytes in PBS, serial 
dilutions (achieved by adding either 0, 20, 40, 80, 100 or 120 μL) of TSE or 68 mM ascorbate 
were added, and the mixture was adjusted with PBS to 1.77 mL of final volume. To this, 100 μL 
of 400 μM H2O2 (in PBS pH 7.4) was added, giving a total reaction volume of 1.87 mL. The 
reaction mixture was shaken gently while being incubated at 37 °C for 3 h. The reaction mixture 
was diluted with 8 mL of PBS and centrifuged at 2000 × g for 10 min. The absorbance of the 
resulting supernatant was measured at 540 nm by spectrophotometer to determine the extent of 
hemolysis. The percentage of hemolysis was calculated by taking hemolysis caused by a blank 
control (100 μL of 400 μM H2O2 without TSE or ascorbate) as 100%. The protective effect of 
TSE against oxidative damage by tert-butyl-hydroperoxide (t-BOOH) was performed on the 
basis of a fluorescence cytolysis assay (Nakamura et al., 2001). 105 Jurkat cells loaded with 
Calcein-AM were plated per well in a 96-well plate in DME-medium with 3% FBS and 0.04% 
Trypan Blue. Then t-BOOH was added to the wells at a final concentration of 4 mM. Increasing 
concentrations of TSE were added to generate the set of curves shown. Fluorescent density was 
measured with excitation at 485 nm and emission at 520 nm. To test the ability of TSE to protect 
HIV virions from damage by t-BOOH, identical amounts of HIV-1 viral stocks were added to 
200 μL of media containing t-BOOH, t-BOOH/TSE or PBS control and maintained at room 
temperature for 1 h. Following these treatments, virions were collected by centrifugation at 
30,000 × g for 100 min. Resuspended virus was used to infect TZM-bl cells to measure the 
infectivity. 
 
2.6. Effect of TSE on HIV infectivity in both TZM-bl cells and Jurkat T cells 
 
For TZM-bl cells, 1.2 × 104 cells were plated on a 96-well plate and pre-incubated with serial 
dilutions of TSE in 200 μL of medium. The cells were then infected with HIV-1 (MOI = 0.1); 
after 48 h incubation, luciferase activities were measured. For Jurkat cells, 1 × 106 cells were 
infected with HIV-1 (MOI = 0.1), then treated with either PBS vehicle or TSE (2 μL per 200 μL 
of culture medium) for 2 days. The relative HIV titers in 100 μL of the supernatants were then 
detected in TZM-bl cells as described above. 
 
2.7. Vector construction and cell transfection 
 
Based on the pHIV-lacZ expression vector (NIH AIDS Research and Reference Reagent 
program Cat # 151), vector pHIV-4NF was generated with four copies of the NF-κB site in the 
HIV-LTR region. The vector was used in studying the effect of TSE on NF-κB activation. Hela 
cells (8 × 104) were co-transfected with pHIV-4NF and pGL-2 (transfection efficiency control) 
with Lipofectamine 2000 (Invitrogen), then treated with PBS, TSE or TNF-α. At 48 h post-
transfection, β-galactosidase and luciferase activities were measured in cell lysates. 
 
2.8. mRNA microarray assay 
 
Human Jurkat T cells were treated with a non-toxic dose of TSE overnight, then total cellular 
RNA was prepared and purified by standard methods and sent for RNA microarray analysis, 
along with mRNA from cells treated with PBS alone as a control. The samples were run on 
Affymetrix HG-U133 Plus 2.0 chips at the MicroArray Core at Wake Forest University, Winston 
Salem, NC. 
 
3. Results 
 
3.1. Toxicity of TSE on TZM-BL cells 
 
As assessed by the MTT cell viability assay, TSE shows dose dependent cellular toxicity in 
TZM-bl cells (Fig. 1). At dilutions as low as 0.15 μL of TSE in 200 μL of cell culture medium, 
TSE shows a mild proliferative effect, whereas amounts larger than 5 μL of TSE per 200 μL of 
culture medium show increasing toxicity to cells. Therefore, a dose of 2 μL per 200 μL 
microplate well (i.e., 1% TSE in culture media) was used as the standard dose for HIV 
stimulation in later experiments. 
 
 
Figure 1. Effect of TSE on cell proliferation and viability. After 48 h exposure to various 
concentrations of TSE, cell viability of TZM-bl cells was assessed using the MTT assay. The x-
axis corresponds to the volume of TSE (data points from 0.15 to 20 μL) added to 200 μL final 
volume of culture medium. At around 1 μL, there is a trend towards a slight proliferative effect 
(∼20% increase) on cells. At 5 μL and above, there is a significant decrease in the number of 
viable cells. At 2 μL per 200 μL media (1% TSE) there is no significant effect, either positive or 
negative, on cell proliferation; this concentration was used in subsequent experiments unless 
otherwise stated (in this and all subsequent figures, data are from three independent experiments; 
error bars represent SEM). 
 
3.2. TSE enhances HIV virion production/infectivity in both T cells and CD4+ Hela (TZM-bl) 
cells 
 
As shown in Fig. 2A, TSE enhances HIV-1 infectivity in TZM-bl from doses as low as 0.15–
5 μL TSE, with final dilution to 200 μL of culture medium. Based on the dose–response curve 
of Fig. 2A, an optimal “HIV stimulating” dose of TSE of 2 μL per 200 μL medium was used for 
further studies in other cell lines; at this dose, there is a negligible effect on T cell proliferation 
per se (Fig. 1). Various antioxidants (including a combination of glutathione and selenium, or 
vitamin C alone) were unable to block the stimulating effect of TSE on HIV infectivity. The 
effect of TSE on HIV production was also tested in human Jurkat T cells. As shown in Fig. 2B, 
when Jurkats were infected with HIV, with and without TSE, and the supernatants tested for HIV 
titers in TZM-bl cells, HIV production increased over 50% following TSE stimulation 
(P < 0.0004, n = 3), comparable to the direct HIV-simulating effect of TSE in TZM-bl cells 
alone (Fig. 2A). 
 
 
Figure 2. TSE enhances HIV infectivity. (A) The y-axis represents luciferase production in TSE 
or nicotine-treated TZM-bl cells infected with HIV-1, relative to untreated HIV-infected cells. 
Thus 100% enhancement represents a doubling of viral infectivity relative to the control. The x-
axis represents volume added in μL for TSE (as in Fig. 1), and final μM concentration for 
nicotine. Increasing concentrations of TSE enhance HIV infectivity to a maximum at 2.5 μL TSE 
per 200 μL media; at higher concentrations, there is a decline, probably due to the cytotoxicity of 
TSE at high concentrations (Fig. 1). Nicotine shows no enhancement at concentrations from 
0.075 to 5 μM. (B) In Jurkat T cells, HIV production was increased by 51% (P < 0.0004) 
following stimulation with TSE. (The y-axis shows light units from luciferase activity; these 
units are only significant in relative terms). 
 
3.3. Nicotine alone shows no enhancement of HIV infectivity 
 
Since TSE showed an enhancing effect on HIV infectivity, the corresponding equivalent 
concentrations of nicotine were tested to see if it has a similar effect. As shown in Fig. 2A, 
nicotine alone has no effect on HIV infectivity at concentrations of up to 5 μM (about 5 times 
higher than the nicotine levels in the “standard” dose of 1% TSE). This rules out the possibility 
that nicotine alone can contribute to the enhancing effect of TSE on HIV infectivity. 
 
3.4. Increased HIV infectivity is not due to chemical tobacco additives: TSE from a “natural” 
tobacco shows a similar enhancing effect on HIV infectivity 
 
Since Marlboro Lights may contain some “flavor” additives in addition to tobacco, TSE from 
American Spirit brand cigarettes, which are claimed to contain no additives, was also prepared. 
Both TSEs show an identical enhancing effect on HIV infectivity. Thus this effect is not due to a 
chemical additive, but rather, must be caused by some natural tobacco constituent(s). 
 
3.5. TSE does not activate NF-κB or HIV LTR signaling 
 
One possible mechanism whereby smoking might activate HIV is via stimulation of NF-κB, 
which can be activated by oxidant stimuli. Because smoking has been suggested to activate the 
NF-κB signaling pathway (Hasnis et al., 2007), we asked if TSE has the same effect on the HIV-
LTR enhancer region which contains two copies of the NF-κB binding site. Based on the pHIV-
lacZ expression vector pHIV-LacZ, a construct with four copies of the NF-κB site in the HIV-
LTR region (pHIV-4NF) was generated (2.7). When Hela cells were transfected with this vector 
and treated with TSE (final conc. of 1%), the results showed that TSE has no significant effect 
on the HIV-LTR or NF-κB activation in this in vitro system (P > 0.05, n = 3, Fig. 3). The 
observation that this increased infectivity is not NF-κB mediated, along with the inability of 
antioxidants to block the enhancing effect of TSE on HIV virus production (Section 3.2), 
suggests that this effect is not a result of oxidative stress due to TSE components. 
 
 
Figure 3. TSE shows no activation effect on NF-κB of HIV-LTR. Hela cells were co-transfected 
with pHIV-4NF and pGL-2 (transfection efficiency control), then treated with PBS, TSE or 
TNF-α as a positive control for NF-κB stimulation. Luciferase reporter activity was not 
significantly different between saline control and TSE treatments (*). 
 
3.6. TSE oxidation/reduction potential assays 
 
Since TSE is unable to activate NF-κB or other sites in the HIV LTR, we decided to directly test 
whether TSE has pro-oxidant activity, which had seemed a likely assumption. A ferric reducing 
power-based antioxidant capacity assay (Berker et al., 2007) and the ferric reducing ability of 
plasma (FRAP) method were both used in cell-free assays to measure TSE total antioxidant 
activity (Benzie and Strain, 1996). Surprisingly, TSE proved to have a net antioxidant rather than 
oxidant activity (Fig. 4A and B), and its reducing power is almost as great as a 1 mM solution of 
ascorbate (Fig. 4A). 
 
 
Figure 4. Antioxidant activity of TSE. (A) Cell free reducing power. 30–300 μL (x-axis) of TSE 
was added to 5 mL ferric reducing power-based antioxidant capacity assay solution, and 
compared to the same volume of 1 mM ascorbate alone as a positive control. The results show 
that the TSE stock solution is almost as potent a reducing agent as 1 mM ascorbate. (B) Cell free 
FRAP assay. 3–30 μL of TSE was added to 300 μL of FRAP assay solution to assess antioxidant 
power of TSE and its additive effect with ascorbate, with comparison to a Fe+2 standard curve 
(the x-axis indicates μL volume added of either stock TSE, 1 mM ascorbate, or 0.1 mM ferrous 
sulfate). (C) Anti H2O2-induced hemolysis assay. In the non-toxic range, TSE shows a strong 
inhibitory effect on H2O2-induced hemolysis. The x-axis shows volume in μL of TSE or 68 mM 
ascorbate stock solutions added to a final volume of just under 2 mL, corresponding to a final 
concentration range of approximately 1–6% TSE and 1–4 mM ascorbate. (D) Protective effect of 
TSE against oxidant challenge in Jurkat T cells. Even at the highest dilution (as low as 0.3 μL 
into 200 μL of culture medium, omitted from graph for clarity), up to 5 h or more after treatment, 
TSE has a significant protective antioxidant effect against challenge with tert-butyl 
hydroperoxide (t-BOOH). 
 
3.7. Carbon monoxide is not a reductive constituent in TSE and shows no effect on HIV 
infection/infectivity 
 
Carbon monoxide (CO) is a significant product of tobacco combustion, and is substantially 
soluble in water. Thus, it is probably present in TSE, and, being in a reduced state relative to 
carbon dioxide, it has the potential to act as a reducing agent, e.g., to reduce ferric iron (Bickar et 
al., 1984). Thus, it seemed possible that CO could be responsible for the reducing activity of TSE 
observed in the assays shown in Fig. 4A and B. A saturated CO solution was tested in the FRAP 
assay; the result shows that CO has no detectable antioxidant activity by this method. A PBS 
solution saturated with CO was also tested for its ability to stimulate HIV in TZM-bl; it had no 
detectable effect on HIV production/infectivity. 
 
3.8. Ability of TSE to protect cells against oxidant challenge 
 
Because TSE has antioxidant activity in the cell free FRAP assay (Fig. 4A and B), to answer 
whether TSE can protect cells from oxidative stress, human blood cells were used to test its 
antioxidant activity in a hemolysis assay. TSE showed a strong protective effect against 
H2O2 induced hemolysis (Fig. 4C). The fluorescent cytoplasmic dye Calcein can be used as cell 
membrane permeability marker; this is the basis of a fluorescence cytolysis assay (Nakamura et 
al., 2001), which was applied to study the antioxidant activity of TSE against t-BOOH-induced 
oxidative damage to Jurkat T-cells. The result showed that TSE can protect cells from oxidative 
stress (Fig. 4D); this is consistent with the antioxidant activity of TSE observed in Fig. 4A and B. 
 
3.9. TSE protects HIV virions against tert-butyl-hydroperoxide 
 
As shown in Fig. 5, in addition to its ability to protect cells against oxidant damage (Fig. 4C and 
D), TSE confers significant protection to HIV virions from exposure to a potent oxidant, t-
BOOH, as the t-BOOH-exposed virus retains its ability to replicate at the same level as the 
control untreated virus only when TSE is present (P < 0.001, n = 3). 
 
 
Figure 5. TSE protects HIV-1 virions from damage by tert-butyl hydroperoxide. Identical 
amounts of HIV-1 viral stocks were added to 200 μL of media containing 4 mM t-BOOH, 4 mM 
t-BOOH plus 1% TSE, or saline (left bar labeled “virus”) at room temperature for 1 h. Following 
these treatments, virions were collected by centrifugation and resuspended virus was used to 
infect TZM-bl cells to measure the infectivity. 1% TSE provided complete protection against t-
BOOH induced damage to viral viability/infectivity. 
 
3.10. TSE regulates cellular gene expression 
 
In the light of the foregoing results showing that TSE can enhance HIV infectivity in a nicotine-
independent manner, and that this effect is not mediated via activation of the viral LTR, it was 
evident that the most effective way to proceed would be to study the effect of the active tobacco 
constituents on cellular gene expression, in order to better understand how TSE might be 
modulating the process of HIV infection. Because human T cells are a primary HIV infection 
target, the effect of tobacco constituents and TSE on cell gene expression in T cells, as opposed 
to other cell types, ought to be more meaningful for understanding the interaction of tobacco 
constituents and HIV infection. Thus, human Jurkat T cells were treated with a non-toxic dose of 
TSE (1% relative to culture medium) and used for the microarray studies. The resulting 
microarray gene expression profiles (Table 1) showed that the expression of more than a dozen 
genes was altered 3 fold or higher by TSE treatment. One group of genes is involved in different 
stages of HIV infection; significantly, all these genes are up-regulated by TSE. Another group of 
affected genes have redox-related functions, as discussed below. 
 
Table 1. Genes whose expression is most significantly altered by TSE exposure in Jurkat T cells. 
Genes 
Accession 
numbers Functions Refs. 
Up-regulated genes 
CD59, protectin NM_000611 Protects virions from complement mediated 
destruction 
Bohana-Kashtan et al. (2004) 
Calmodulin1 NM_006888 Binds HIV gp160 and mediates gp160 enhanced 
apoptosis 
Micoli et al. (2000) 
TAX1BP1 NM_006024 Indirectly binds with viral LTR Chin et al. (2007) 
Coatomer protein complex b-2 NM_004766 Golgi budding and vesicular trafficking Benichou et al. (1994) 
Sjogren syndrome antigen B NM_003142 Enhances HCV replication Domitrovich et al. (2005) 
DDX3 NM_001356 Required for HCV replication Ariumi et al. (2007) 
HSP90 β 1 NM_003299 P-TEFβ-mediated Tat transactivation. O’Keeffe et al. (2000) 
Thioredoxin-related 
transmembrane protein 1 
NM_030755 Involved in clathrin-mediated endocytosis and 
HIV mediated downregulation of CD4; a 
coreceptor of coxsakie B virus 
Toh et al. (2005) 
Down regulated genes 
Thioredoxin (Trx) interacting 
protein 
NM_006472 Binds and inhibits the reducing activity of Trx Maulik and Das (2008), 
Nakamura et al. (1996) 
PHGPX NM_002085 Inhibits NF-κB activation Brigelius-Flohe et al. (1997) 
Stearoyl-CoA desaturase AA678241 Essential for the assembly of VLDL particles Miyazaki et al. (2000) 
MHC, HLA-E NM_005516 When down-regulated, protects the virus from 
MHC I-restricted cytotoxic T-lymphocytes 
Williams et al. (2002) 
 
4. Discussion 
 
Few studies have explored the possibility of direct interactions between non-nicotine tobacco 
constituents and viral replication in HIV/AIDS. The current study has identified direct 
interactions between tobacco constituents and HIV/AIDS infection at both the virion and cellular 
levels. The data show that as-yet unidentified non-nicotine smoke constituents are involved in 
enhancing HIV infectivity/virus production. We propose here that the mechanism involved in 
smoke-enhanced stimulation of HIV production involves an increase in HIV infectivity rather 
than direct activation of HIV replication. This follows from the key observation that TSE has 
absolutely no transactivating effect on the HIV LTR promoter/enhancer (Fig. 3), so the increased 
virus production observed is not due to a direct effect on viral mRNA transcription. 
 
Over the past few decades, much of the emphasis of research on tobacco constituents has been 
placed on the formation and identification of toxic and tumorigenic agents in tobacco smoke 
(Hoffmann and Wynder, 1986). Our results rule out nicotine at any physiologically relevant 
concentration as the key activator of HIV, due to its inability to mimic TSE at concentrations up 
to 2.5 μM, about 10 times higher than the median concentration of nicotine in the plasma of 
smokers (Taylor et al., 1986). 
 
Transforming growth factor-beta1 (TGF-β1) has been suggested to be involved in the enhanced 
expression of HIV-1 by nicotine (Rock et al., 2008), but in the current studies and in one other 
report (Maunders et al., 2007), TGF-β1 was found to be down-regulated. 
 
Oxidative stress and the lipid peroxidation it induces are obvious candidates for potential 
involvement in the mechanism of the interaction between tobacco smoking and HIV/AIDS. The 
NF-κB signaling pathway is believed to be activated during the interaction (Hasnis et al., 2007). 
 
Our results show that TSE has sufficient antioxidant potential to protect cells and virions from 
oxidative damage (Fig. 4, Fig. 5). The finding that TSE has the ability to protect against 
oxidative damage goes against the prevailing view in which tobacco smoke is generally 
considered to be a fundamentally oxidative agent. This is a highly significant result in regard to a 
possible cell-independent mechanism whereby TSE could increase HIV infectivity, by stabilising 
the virion against degradation and oxidative attack, e.g., by the “respiratory burst” of 
lymphocytes. 
 
Gene expression profiles have also shown that TSE can down-regulate thioredoxin (Trx)-
interacting protein (TXNIP), thus increasing Trx activity. In the current in vitro studies, TSE 
showed no activating effect on an HIV-LTR reporter expression vector which bears 4 copies 
(double the normal number) of the NF-κB binding site in the enhancer region. 
 
The interactions between tobacco constituents and tobacco smoke on gene expression have been 
extensively studied previously by microarray on different cell types. The fact that the observed 
gene expression profiles are different one from another may be due to differences in the cell type 
used. A study in oral leukoplakia cells treated with TSE showed that genes whose expression 
was altered grouped into different pathways such as cell proliferation, inflammation, apoptosis, 
coagulation, and tumor suppression (Gumus et al., 2008). Specifically, epidermal growth factor 
receptor (EGFR) related networks as well as several aryl hydrocarbon receptor-dependent genes 
such as cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) and cytochrome 
P450, family 1, subfamily B, polypeptide 1 (CYP1B1) were induced. Notably, CYP1A1 and 
CYP1B1 levels were increased in the oral mucosa of smokers. 
 
Macrophages are key inflammatory cells in chronic obstructive pulmonary disease (COPD). 
When monocyte derived macrophages (MDMs) from whole blood from patients with COPD 
were stimulated with cigarette smoke extract (CSE) for 6 h, microarray analysis revealed that IL-
8 mRNA levels were up-regulated; other cytokines and chemokines were down-regulated. The 
expression of the NF-κB component p50 and IκBα were suppressed by CSE, while there was up-
regulation of the AP-1 components c-Jun, FOSL1 and FOSL2. The effects of acute CSE 
exposure appear to encompass both up-regulation of chemotaxis mechanisms through IL-8, but 
also down-regulation of innate immunity (Kent et al., 2008). 
 
When tracheobronchial epithelium was exposed to air or whole cigarette smoke for 1 h in a 
specially designed chamber, gene expression was altered in cellular processes including 
xenobiotic metabolism, oxidant/antioxidant balance, and DNA damage and repair. Notably, there 
was marked down-regulation of the transforming growth factor-β pathway (Maunders et al., 
2007). TGF-β1 is reported to be upregulated in microgial cells by nicotine pre-incubation (Rock 
et al., 2008). 
 
RNA microarray results from the current study are different from the reported nicotine-altered 
gene expression profile of HIV infected microglial cells (Rock et al., 2008). Transforming 
growth factor β-1, for example, is up-regulated in nicotine-treated microglial cells. However, it is 
actually down-regulated in TSE treated human T-cells. The differences between the current 
results and those reported previously (Rock et al., 2008) may be due to the difference in cell type 
and the treatments, i.e., pure nicotine verses TSE (a complex mixture). 
 
There are two groups of genes that show significantly altered expression levels (3 fold or more) 
in human T cells treated with TSE in the current study. One group of genes is involved in 
different stages of HIV infection. All these genes are up-regulated by TSE. CD59 (also called 
protectin) can incorporate into HIV-1 particles and protect virions from complement-mediated 
destruction (Bohana-Kashtan et al., 2004); Calmodulin1 binds HIV gp160 and mediates gp160 
enhanced apoptosis (Micoli et al., 2000); human T-cell leukemia virus type I binding protein 1 
(TAX1BP1) indirectly binds to LTR (Chin et al., 2007); Coatomer protein complex b-2 is 
essential for golgi budding and vesicular trafficking (Benichou et al., 1994); HSP90 beta 1 is 
responsible for positive transcription elongation factor b (P-TEFb)-mediated HIV Tat 
transactivation (O’Keeffe et al., 2000); thioredoxin-related transmembrane protein 1 is involved 
in HIV-mediated down-regulation of CD4 and is also a co-receptor of coxsackie B virus (Toh et 
al., 2005). There are two up-regulated genes related to HCV infection. DEAD (Asp–Glu–Ala–
Asp) box polypeptide 3 (DDX3) is needed for HCV replication (Ariumi et al., 2007); Sjogren 
Syndrome antigen B (SSB) can enhance HCV replication (Domitrovich et al., 2005). HCV 
infection is common in HIV/AIDS, particularly in injection drug users, and also in crack smokers 
(Shannon et al., 2008). Apparently, from our results, tobacco smoke may be harmful especially 
for HIV/or HCV carriers because TSE stimulates expression of these genes and thereby may 
affect virus production. 
 
Another group of affected genes is characterized by redox-related functions. Trx interacting 
protein (TXNIP) is down-regulated by TSE. TXNIP acts as an endogenous inhibitor of the 
reducing ability of Trx, by interacting directly with the catalytic center of reduced Trx (Maulik 
and Das, 2008). The Trx system plays a vital role in the maintenance of a reduced intracellular 
redox state. Trx plays a role in limiting oxidant stress through either its direct effect as an 
antioxidant, or through its interactions with TXNIP (Maulik and Das, 2008). Therefore, 
inhibition of TXNIP by smoking could potentially rescue and increase Trx reducing activity. 
Interestingly, HIV/AIDS patients show elevated levels of Trx in plasma (Nakamura et al., 1996) 
and this elevation is a significant predictor of mortality in HIV infection (Nakamura et al., 2001). 
Phospholipid hydroperoxide glutathione peroxidase (PHGPX) is also down-regulated by TSE. 
This enzyme is located on cellular membranes, where it serves to protect membrane lipids from 
peroxidation (Brigelius-Flohe et al., 1997). Lastly, several genes whose functions are related to 
very-low-density lipoprotein (VLDL) assembly (Miyazaki et al., 2000) and major 
histocompatibility complex I (MHC-I) antigen presentation (Williams et al., 2002) are also 
down-regulated in TSE treated cells. This suggests the hypothesis that although tobacco smoke 
may down-regulate cellular membrane PHGPX and thereby cause membrane peroxidation, at the 
same time, tobacco smoke can increase the intracellular redox potential via increased Trx, which 
may protect virions and infected cells from oxidant damage. 
 
In conclusion, we have revealed a novel aspect of the interaction between tobacco smoking and 
HIV infectivity, and identified cellular genes and mechanisms that are potentially involved. 
Furthermore, constituents of tobacco smoke other than nicotine and carbon monoxide are 
responsible for the increased HIV infectivity and virus production. Given that tobacco smoke 
contains more than 3900 constituents, a reasonably comprehensive study of the effects of 
smoking on HIV infectivity has the potential to reveal a novel viral activation mechanism, for 
which inhibitors could be discovered, giving a new way to inhibit the spread of HIV, and to 
potentially reduce pathologies in HIV-infected smokers. 
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